Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1959 1
1962 3
1963 1
1964 1
1965 1
1967 1
1968 1
1969 3
1971 1
1972 1
1974 4
1975 9
1976 3
1977 4
1978 2
1979 5
1980 2
1981 1
1982 6
1983 4
1984 8
1985 11
1986 9
1987 18
1988 23
1989 32
1990 26
1991 35
1992 18
1993 37
1994 33
1995 47
1996 37
1997 52
1998 48
1999 73
2000 56
2001 84
2002 102
2003 127
2004 152
2005 183
2006 188
2007 223
2008 268
2009 349
2010 393
2011 435
2012 516
2013 631
2014 649
2015 713
2016 760
2017 780
2018 835
2019 915
2020 1082
2021 1231
2022 1393
2023 1359
2024 1438
2025 1657
2026 41

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

15,305 results

Results by year

Filters applied: . Clear all
Page 1
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Bang YJ, et al. Among authors: kang yk. Lancet. 2010 Aug 28;376(9742):687-97. doi: 10.1016/S0140-6736(10)61121-X. Epub 2010 Aug 19. Lancet. 2010. PMID: 20728210 Clinical Trial.
Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B, Chan SL, Kelley RK, Lau G, Kudo M, Sukeepaisarnjaroen W, Yarchoan M, De Toni EN, Furuse J, Kang YK, Galle PR, Rimassa L, Heurgué A, Tam VC, Van Dao T, Thungappa SC, Breder V, Ostapenko Y, Reig M, Makowsky M, Paskow MJ, Gupta C, Kurland JF, Negro A, Abou-Alfa GK; HIMALAYA investigators. Sangro B, et al. Among authors: kang yk. Ann Oncol. 2024 May;35(5):448-457. doi: 10.1016/j.annonc.2024.02.005. Epub 2024 Feb 19. Ann Oncol. 2024. PMID: 38382875 Free article. Clinical Trial.
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG; GRID study investigators. Demetri GD, et al. Among authors: kang yk. Lancet. 2013 Jan 26;381(9863):295-302. doi: 10.1016/S0140-6736(12)61857-1. Epub 2012 Nov 22. Lancet. 2013. PMID: 23177515 Free PMC article. Clinical Trial.
Targeting FSP1 triggers ferroptosis in lung cancer.
Wu K, Vaughan AJ, Bossowski JP, Hao Y, Ziogou A, Kim SM, Kim TH, Nakamura MN, Pillai R, Mancini M, Rajalingam S, Han M, Nakamura T, Wang L, Chung S, Simeone D, Shackelford D, Kang YP, Conrad M, Papagiannakopoulos T. Wu K, et al. Among authors: kang yp. Nature. 2025 Nov 5. doi: 10.1038/s41586-025-09710-8. Online ahead of print. Nature. 2025. PMID: 41193800
Olezarsen for Managing Severe Hypertriglyceridemia and Pancreatitis Risk.
Marston NA, Bergmark BA, Alexander VJ, Prohaska TA, Kang YM, Moura FA, Zimerman A, Waldman E, Weinland J, Murphy SA, Goodrich EL, Zhang S, Xia S, Li D, Goldberg AC, Goudev A, Badimon L, Kiss RG, Vrablik M, Gaudet D, Moulin P, Stroes ESG, Banach M, Cohen H, Blom D, Charng MJ, Nordestgaard BG, Nicholls SJ, Tsimikas S, Giugliano RP, Sabatine MS; CORE-TIMI 72a and CORE2-TIMI 72b Investigators. Marston NA, et al. Among authors: kang ym. N Engl J Med. 2025 Nov 8. doi: 10.1056/NEJMoa2512761. Online ahead of print. N Engl J Med. 2025. PMID: 41211918
The burden of cardiovascular disease attributable to high systolic blood pressure across China, 2005-18: a population-based study.
Cao X, Zhao Z, Kang Y, Tian Y, Song Y, Wang L, Zhang L, Wang X, Chen Z, Zheng C, Tian L, Yin P, Fang Y, Zhang M, He Y, Zhang Z, Weintraub WS, Zhou M, Wang Z; China Burden of Disease Attributable to Risk Factors Collaborative Group. Cao X, et al. Among authors: kang y. Lancet Public Health. 2022 Dec;7(12):e1027-e1040. doi: 10.1016/S2468-2667(22)00232-8. Lancet Public Health. 2022. PMID: 36462514 Free article.
CDH1 Orchestrates Anabolic Events to Promote Cell Cycle Initiation.
Mao YZ, Zhang JJ, You MQ, Wang H, Lin Y, Fang Y, Zhang HL, Qu YY, Zhou Q, Wang M, Li G, Guo ZF, Xu M, Liu J, Lin PC, Yuan YY, Kang Y, Zhao SM, Xu W. Mao YZ, et al. Among authors: kang y. Adv Sci (Weinh). 2025 Dec;12(47):e07584. doi: 10.1002/advs.202507584. Epub 2025 Sep 29. Adv Sci (Weinh). 2025. PMID: 41020695 Free PMC article.
15,305 results
You have reached the last available page of results. Please see the User Guide for more information.